VistaGen Therapeutics Inc. (NASDAQ: VTGN) Preclinical Study Data Show Drug Combo’s Innovative Potential in Fight Against Major Depressive Disorder
Study results have exciting therapeutic potential across wide range of CNS indications. VTGN focused on developing new generation of medications…